Holen Sie sich die Stockscreener-App
2.96
6.33%
-0.20
Vorhandelsmarkt:
3.07
0.11
+3.72%
Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten
Rocket Pharmaceuticals Names Christopher Stevens as Chief Operating Officer - MarketScreener
ROSEN, A TOP-RANKED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT - TradingView
Faruqi & Faruqi Notifies Rocket Pharmaceuticals Investors of a Class Action Lawsuit and Upcoming DeadlineRCKT - StreetInsider
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesRCKT - WV News
Rocket Pharmaceuticals names Christopher Stevens as chief operating officer - Investing.com
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) - GlobeNewswire
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class - GlobeNewswire
Shareholders that lost money on Rocket Pharmaceuticals, Inc.(RCKT) should contact Levi & Korsinsky about pending Class ActionRCKT - WV News
Investor Alert: Securities Class Action Filed Against Rocket Pharmaceuticals (RCKT) - TradingView
Rocket Pharmaceuticals, Inc. Sued for Securities Law - GlobeNewswire
ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) SHAREHOLDER - GlobeNewswire
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar
Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy - Yahoo Finance
Levi & Korsinsky Urges Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Act Before Lead Plaintiff Deadline August 11, 2025 - ACCESS Newswire
RCKT Investors With Large Losses are Encouraged to Contact - GlobeNewswire
Rocket Pharmaceuticals, Inc. Investors: Please contact the - GlobeNewswire
INVESTOR NOTICE: Rocket Pharmaceuticals, Inc. (RCKT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Robbins Geller - GlobeNewswire
INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. (RCKT) - GlobeNewswire
ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) INVESTOR ALERT: - GlobeNewswire
Investors who lost money with shares of Rocket Pharmaceuticals, - openPR.com
Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Benzinga
Rocket Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
RCKT INVESTOR NOTICE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - FinancialContent
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $5.00 at UBS Group - Defense World
RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
Rocket Pharmaceuticals (RCKT) Price Target Lowered by Analyst | - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - PR Newswire
UBS Cuts Price Target on Rocket Pharmaceuticals to $5 From $12, Maintains Buy Rating - MarketScreener
UBS Adjusts Price Target for Rocket Pharmaceuticals (RCKT) Amid Program Developments | RCKT Stock News - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. LawsuitRCKT - PR Newswire
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi ... - Bluefield Daily Telegraph
Investors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your RightsRCKT - GuruFocus
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Rocket Pharmaceuticals, Inc. (RCKT) - ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - marketscreener.com
RCKT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RCKT Investor Notice: Robbins LLP Reminds Shareholders of - GlobeNewswire
Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal year ahead By Investing.com - Investing.com South Africa
Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal year ahead - Investing.com Australia
RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Rocket - GlobeNewswire
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ROCKET ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Urged to Join Class Action Before August 11, 2025Contact Levi & Korsinsky - ACCESS Newswire
ROSEN, A LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT - TradingView
RCKT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action - ACCESS Newswire
Contact Levi & Korsinsky by August 11, 2025 Deadline to - GlobeNewswire
RCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Business Wire
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy TrialHagens Berman - PR Newswire
Contact Levi & Korsinsky by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc.(RCKT) - PR Newswire
Join Class Action to Recover Losses from Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky Before August 11, 2025 - ACCESS Newswire
Shareholder Alert: Robbins LLP Informs Investors of the Rocket Pharmaceuticals, Inc. Class Action - Eastern Progress
RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit - PR Newswire
2.10%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):